CROI 2015 Program and Abstracts

Poster Listings

THURSDAY, FEBRUARY 26, 2015 Session P-N8 Poster Session

677 HIV/HCV Co-Infection Accelerated Liver Disease is AssociatedWith Induction of M2-Like Macrophages Moses T. Bility 1 ; Feng Li 1 ; Junichi Nunoya 1 ; Guangming Li 1 ; Eoin Feeney 2 ; Raymond Chung 2 ; Lishan Su 1 1 University of North Carolina, Chapel Hill, NC, US; 2 Massachusetts General Hospital, Harvard Medical School, Boston, MA, US 678 HIV Infection Is AssociatedWith an Impaired Anti-HCV Activity of NK-Like T Cells Pavlos Kokordelis 1 ; Benjamin Krämer 1 ; Christoph Boesecke 1 ; EstherVoigt 2 ; Patrick Ingiliz 3 ; Andreas Glässner 1 ; FranziskaWolter 1 ; Ulrich Spengler 1 ; Jürgen K. Rockstroh 1 ; Jacob Nattermann 1 1 University of Bonn, Bonn, Germany; 2 Praxis am Ebertplatz, Cologne, Germany; 3 Medical Center for Infectious Diseases, Berlin, Germany 679 Dys-Regulated Cross Talk Between CD4+ T Cells and NK Cells in HIV/HCV Coinfection Benjamin Krämer 1 ; Andreas Glässner 1 ; Claudia Zwank 1 ; Felix Goeser 1 ; Christoph Boesecke 1 ; Patrick Ingiliz 2 ; Christian P. Strassburg 1 ; Ulrich Spengler 1 ; Jürgen Rockstroh 1 ; Jacob Nattermann 1 1 University of Bonn, Bonn, Germany; 2 Medical Center for Infectious Diseases, Berlin, Germany 680 HIV/HCV Coinfection Is AssociatedWith Significant Alterations of the NK Cell Pool Dominik J. Kaczmarek 1 ; Pavlos Kokordelis 1 ; Benjamin Krämer 1 ; Andreas Glässner 1 ; FranziskaWolter 1 ; Patrick Ingiliz 2 ; Christian P. Strassburg 1 ; Ulrich Spengler 1 ; Jürgen Rockstroh 1 ; Jacob Nattermann 1 1 University of Bonn, Bonn, Germany; 2 Medical Center for Infectious Diseases, Berlin, Germany 681 Dynamic Changes of CXCL10 Isoforms and DPP4 During IFN-Free Treatment for HCV Eric G. Meissner 1 ; Jeremie Decalf 2 ; Armanda Casrouge 2 ; Henry Masur 3 ; Shyam Kottilil 4 ; Darragh Duffy 2 ; Matthew L. Albert 2 1 Medical University of South Carolina, Charleston, SC, US; 2 Institut Pasteur, Paris, France; 3 National Institutes of Health (NIH), Bethesda, MD, US; 4 University of Maryland School of Medicine, Baltimore, MD, US 682 Mx1 and OAS1-2 SNPs Are RelatedWith Severity of Liver Disease in HIV/ HCV Coinfection Mónica García-Álvarez 1 ; Juan Berenguer 2 ; Daniel Pineda-Tenor 1 ; Maria Ángeles Jiménez- Sousa 1 ; María Guzmán-Fulgencio 1 ; Ana Carrero 2 ;Teresa Aldamiz-Echevarria 2 ; Francisco Tejerina 2 ; Cristina Diez 2 ; Salvador Resino 1 1 Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain; 2 Hospital General Universitario Gregorio Marañón, Madrid, Spain 683 Treatment With DCV Plus ASV Reduces Immune Activation in HIV/HCV Coinfected Patients Eleanor M. Wilson 4 ; Anita Kohli 3 ; Julia B. Purdy 3 ; Louisa Howard 1 ; Sabrina Mangat 1 ; GebeyehuTeferi 2 ; John Hogan 2 ; Henry Masur 3 ; Shyam Kottilil 1 1 National Institutes of Health (NIH), Bethesda, MD, US; 2 Unity Health Care, Washington, DC, US; 3 NIH, Bethesda, MD, US; 4 Leidos Biomedical Services, Inc, Bethesda, MD, US 684 Innate Immune Activation Pathways Overlap, Yet Are Distinct in HCV and HIV Infection Lenche Kostadinova ; Benigno Rodriguez; Donald Anthony Case Western Reserve University, Cleveland, OH, US 685 A Novel Mechanism of Resistance to Multiple bNAbs Revealed by Natural Variation in Panel of 199 HCVpp Ramy El-Diwany ; LisaWasilewski; Madeleine Mankowski; Stuart C. Ray; Justin R. Bailey Johns Hopkins University School of Medicine, Baltimore, MD, US 686 Single-Variant Sequencing Revealed Rapid HCV Evolution in HIV Immune Reconstitution

Poster Hall

2:30 pm– 4:00 pm HCV Therapeutics: Preclinical Observations and Clinical Trials of DAAs 687 UNITY-1: Daclatasvir/Asunaprevir/Beclabuvir for HCV Genotype 1 Without Cirrhosis Fred Poordad 1 ,William Sievert 2 , Norbert Brau 3 , Samuel Lee 4 , Jean-Pierre Bronowicki 5 , Ira Jacobson 6 , Eric Hughes 7 , Eugene Swenson 8 , PhilipYin 8 On behalf of the UNITY-1 StudyTeam 1 Texas Liver Institute, San Antonio, Texas, United States; 2 Monash Health and Monash University, Melbourne, Victoria, Australia; 3 Bronx Veterans Affairs Medical Center, New York, New York, United States; 4 University of Calgary, Alberta Health Services, Calgary, Alberta, Canada; 5 Centre Hospitalier Universitaire de Nancy, Universite de Lorraine, Vandoeuvre les Nancy, France; 6 Weill Cornell Medical College, New York, New York, United States; 7 Bristol-Myers Squibb Co, Princeton, New Jersey, United States; 8 Bristol-Myers Squibb Co, Wallingford, Connecticut, United States 688 UNITY-2: Daclatasvir/Asunaprevir/Beclabuvir ± RBV for HCV Genotype 1 With Cirrhosis Andrew Muir 1 , Fred Poordad 2 , Jay Lalezari 3 , Gregory Dore 4 , Christophe Hezode 5 , Alnoor Ramji 6 , Eric Hughes 7 , Eugene Swenson 8 , PhilipYin 88 On behalf of the UNITY-2 StudyTeam 1 Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, United States; 2 Texas Liver Institute, University of Texas Health Science, San Antonio, Texas, United States; 3 Quest Clinical Research, San Francisco, California, United States; 4 Kirby Institute, University of New South Wales Australia, Sydney, New South Wales, Australia; 5 Hópital Henri Mondor, Université Paris-Est, Créteil, France; 6 University of British Columbia, Vancouver, British Columbia, Canada; 7 Bristol-Myers Squibb Co, Princeton, New Jersey, United States; 8 Bristol- Myers Squibb Co, Wallingford, Connecticut, United States 689 Utility of Hepatitis C Viral-Load MonitoringWith Ledipasvir and Sofosbuvir Therapy Sreetha Sidharthan 2 ; Anita Kohli 3 ; Anu Osinusi 2 ; Amy Nelson 1 ; Zayani Sims 2 ; Kerry S. Townsend 4 ; LydiaTang 1 ; Michael Polis 4 ; Henry Masur 2 ; Shyam Kottilil 1 1 Institute of Human Virology, University of Maryland, Baltimore, MD, US; 2 NIH Clinical Center, Bethesda, MD, US; 3 Leidos Biomedical Research, Inc., Frederick, MD, US; 4 National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US 690 Viral Kinetic Profiles of HCV Response to Telaprevir-Based Therapy in Patients With Hemophilia Kenneth E. Sherman 1 ; Ruian Ke 2 ; Susan D. Rouster 1 ; Alan S. Perelson 2 1 University of Cincinnati, Cincinnati, OH, US; 2 Los Alamos National Laboratory, Los Alamos, NM, US 691 Hematologic Analysis of ABT-450/r/Ombitasvir and Dasabuvir + RBV in TURQUOISE-I Robert S. Brown 1 ; DavidWyles 2 ; Jihad Slim 3 ; Peter J. Ruane 4 ; Barbara McGovern 5 ; Roger Trinh 5 ;Yiran Hu 5 ; Joseph J. Eron 6 1 Johns Hopkins University, Baltimore, MD, US; 2 University of California San Diego, La Jolla, CA, US; 3 St Michael’s Medical Center, Newark, NJ, US; 4 Peter J. Ruane MD Inc, Los Angeles, CA, US; 5 AbbVie, Inc, North Chicago, IL, US; 6 University of North Carolina, Chapel Hill, NC, US 692 Effect of HIV Coinfection on Adherence to a 12-Week Regimen of HCV Therapy With Ledipasvir/Sofosbuvir Kerry S. Townsend 1 ;Tess L. Petersen 2 ; Lori A. Gordon 2 ; Amy Nelson 1 ; Cassie Seamon 2 ; Chloe Gross 3 ; Anu Osinusi 2 ; Michael A. Polis 1 ; Henry Masur 2 ; Shyam Kottilil 1 1 National Institute of Allergy and Infectious Diseases, Bethesda, MD, US; 2 National Institutes of Health, Bethesda, MD, US; 3 Leidos Biomedical 18 Research Inc, Frederick, MD, US 693 Investigation of the Role of Macrocyclization in HCV Protease Inhibitor MK-5172 Djadé I. Soumana ; Kristina Prachanronarong; Nese KurtYilmaz; Ali Akbar; Cihan Aydin; Celia A. Schiffer University of Massachusetts Medical School, Worcester, MA, US

Poster Listings

Lin Liu ; David Nardo; Eric Li; GaryWang University of Florida, Gainesville, FL, US

54

CROI 2015